Chemomab Therapeutics - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi CMMB
Chemomab Therapeutics (CMMB) is implementing ESG principles by reducing chemical waste during the development of fibrosis treatments. This EBITDA trend on the current GURU.Markets chart shows that 0.00 is the current metric value. However, financial stability is limited by the risk of failed trials, and a high dependence on a single drug in the portfolio creates a serious vulnerability in the business model.
Ringkesan rincian data analitis Chemomab Therapeutics Ltd. (CMMB)
- nilai saham lan prakiraan konsensus rega:
- rincian nilai pasar emiten:
- indikator kapitalisasi buku:
- rincian struktur utang lan likuiditas bisnis:
Rasio Kabeh Utang marang Dana Pribadi Chemomab Therapeutics|CMMB - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas Chemomab Therapeutics Ltd|CMMB - Gunggung utang perusahaan|Rasio utang marang aset resik Chemomab Therapeutics|CMMB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Chemomab Therapeutics|Rasio jangkoan perantara chemomab.com
- rincian bathi lan kelipatan pasar:
CMMB - Bathi resik perusahaan|Bathi mangsa ngarep Chemomab Therapeutics|CMMB - Pangali P/E|Pangali Forward P/E Chemomab Therapeutics Ltd|CMMB - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Chemomab Therapeutics|CMMB - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Chemomab Therapeutics|CMMB - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan chemomab.com|CMMB - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Chemomab Therapeutics
Ringkesan analitik perusahaan:Chemomab Therapeutics
An investment audit of Chemomab Therapeutics (CMMB) requires an analysis of actual commercial cash flows to assess business viability. This metric captures daily operating income adjusted for non-cash charges, which, in a biotech environment with a minimal ecological footprint and costs limited to waste disposal, allows the EBITDA trend to differentiate seasonal fluctuations from a systemic crisis.
Karo sapa Chemomab Therapeutics saingan
Pendapatan operasional sadurunge ngurangi amortisasi Vertex Corp (VRTX)|ALNY: Bathi operasional sadurunge ngurangi amortisasi|Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi INSM|UTHR: Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi BioMarin Pharmaceutical Inc. (BMRN)|BBIO (BridgeBio Pharma Inc) - Bathi operasional EBITDA|Bathi operasional sadurunge amortisasi BGM (BGM Group Corp)|Bathi operasional sadurunge ngurangi amortisasi COGT (Cogent Biosciences)|XERS (xerispharma.com) - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Keros Therapeutics, Inc. KROS|ARCT (Arcturus Therapeutics Inc) - Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi|Eton Pharma - Bathi operasional EBITDA|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi KMDA (Kamada Pharma)|FULC: Bathi operasional EBITDA|Abeona Therapeutics Inc. (ABEO) - Bathi operasional EBITDA|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Mereo BioPharma Group|PLX: Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Pliant Therapeutics (PLRX)|Bathi operasional sadurunge ngurangi amortisasi appliedtherapeutics.com APLT|Bathi operasional EBITDA RNTX (Rein Therapeutics Inc)|Bathi operasional EBITDA Gelteq Ltd GELS|Aytu Therapeutics - Bathi operasional EBITDA|SRx Health Solutions Inc. (SRXH) - Bathi operasional sadurunge ngurangi amortisasi|PLRZ: Bathi operasional EBITDA|Aeterna Zentaris Inc. - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|CYTH (Cyclo Therapeutics) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Inozyme INZY|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Reneo Pharmaceuticals, Inc. (RPHM)|Bathi operasional sadurunge ngurangi amortisasi COSCIENS Biopharma Inc CSCI
